Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Sanofi-aventis 4Q Profit Sinks 76% On Charge

By Pharmaceutical Processing | February 11, 2009

By GREG KELLER AP Business Writer PARIS (AP) —Sanofi-Aventis SA reported Wednesday a 76 percent drop in fourth quarter net profits, due mainly to a charge for discontinuing two experimental cancer drugs, and announced it would shake up its R&D department. Europe’s third-largest pharmaceutical company — behind GlaxoSmithKline PLC and Novartis AG — said net profit fell to euro182 million ($235 million) in the fourth quarter from euro753 million a year earlier. Sanofi-Aventis took a euro1.43 billion non-cash charge to account for the two drugs’ discontinuation as well as settlement of a patent dispute with Barr Pharmaceuticals Inc. of New Jersey. The Paris-based company, known for its blockbuster blood thinner Plavix and anti-clotting treatment Lovenox, said that on an adjusted basis — that is, not accounting for such charges — its fourth quarter profit rose 13.9 percent to euro1.63 billion, or euro1.25 per share. The company forecast growth in adjusted earnings per share of at least 7 percent this year, down from 11.2 percent in 2008. New Chief Executive Chris Viehbacher, who took over in December, said in a statement that he aims to turn Sanofi-Aventis into “a diversified global leader in healthcare, with one of the most productive research and development in the sector.” To achieve this, Sanofi-Aventis said it will continue to “rationalize” its R&D pipeline to put more focus on “key technologies and diseases.” The company has created two new positions, Chief Medical Officer and Scientific Advisor, to work with current R&D head Marc Cluzel to boost research. Analysts have said the company’s R&D is lacking new drugs to replace those whose patents are expiring in coming years. Sanofi-Aventis also said it would “realign” its industrial capacity to cut costs, without specifying how. Competitors such as Eli Lilly & Co., AstraZeneca PLC, GlaxoSmithKline and Pfizer Inc. — the world’s largest pharmaceutical company — have been shedding thousands of jobs to cut costs. Sanofi-Aventis said it would also look for acquisitions, and named a Chief Strategic Officer to run this effort. “I think the message they’re giving to their market is positive in the sense that they’re going to try to change the situation,” said Gonzalo Moros, pharmaceutical analyst at Madrid-based Ahorro Corporacion Financiera. Moros welcomed the group’s plans to shakeup its R&D division. “They have to focus on more profitable research and development,” Moros said. Sanofi-Aventis’ shares fell 2.5 percent in the fourth quarter. In midday trading in Paris the stock was up 5.9 percent at euro46.58. In November the company abandoned research on diet drug Acomplia, which was once its most promising potential blockbuster treatment but which piled up problems with psychiatric side effects. The company said that for all of 2008, net profit fell 27 percent to euro3.85 billion, on sales that dropped 1.7 percent to euro27.6 billion.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE